title: Treatment of seborrheic dermatitis: comparison of sertaconazole 2 % cream versus pimecrolimus 1 % cream.
abstract: OBJECTIVE
  Seborrheic dermatitis (SD) is an inflammatory skin disorder affecting the scalp, face, and trunk. The treatment of SD is an important issue in dermatology. This study aimed at comparing the efficacy of sertaconazole 2 % cream versus pimecrolimus 1 % cream in the treatment of SD.
  
  
  METHODS
  In this clinical trial study, 60 patients suffering from SD were studied. Thirty patients received local sertaconazole 2 % cream and in control group, 30 patients received pimecrolimus 1 % cream. Patients were recommended to use the cream twice a day for 4 weeks. At the beginning of referring and also 2 and 4 weeks after first visit, the patients were examined by a dermatologist to control improvement of clinical symptoms.
  
  
  RESULTS
  The mean age of members of the sertaconazole and pimecrolimus groups was 30.12 ± 12.56 and 34.67 ± 10.98 years, respectively. The highest level of satisfaction (90 %) was observed 28 days after sertaconazole application since it was 80 % in pimecrolimus group. The relationship between patients' satisfaction and receipt of sertaconazole cream (on the 28th day) was statistically significant (P = 0.006).
  
  
  CONCLUSIONS
  Sertaconazole 2 % cream may be an excellent alternative therapeutic modality for treating SD.
authors.affiliation: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, Drmgoldust@yahoo.com.
authors.forename: M
authors.initials: M
authors.lastname: Goldust
authors.forename: E
authors.initials: E
authors.lastname: Rezaee
authors.forename: R
authors.initials: R
authors.lastname: Raghifar
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D012628:Dermatitis, Seborrheic / Q000175:diagnosis / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007492:Iran; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D063465:Skin Cream; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D007093:Imidazoles; D013876:Thiophenes; C061131:sertaconazole; C117268:pimecrolimus; D016559:Tacrolimus